A 2011 study published by researchers at the Salk Institute in La Jolla, California, demonstrated epigenetic mutations that lasted for at least 30 generations in plants.
Various studies have demonstrated epigenetic down-regulation of key epithelial molecules – such as E-Cadherin.
While this is not always the case, many studies demonstrate that epigenetic variation may be independent of genetic variation (Cubas et al. 1999; Cervera et al. 2002; Riddle and Richards 2002; Keyte et al. 2006; Shindo et al. 2006; Vaughn et al. 2007; Verhoeven et al. 2010; Herrera and Bazaga 2011).
Neuroblastoma may also demonstrate 14q allele loss and Wilms' tumour was of interest as epigenetic alterations at the IGF2/H19 locus are common in this tumour.
Our results demonstrate that epigenetic variation in easily obtainable leukocyte DNA, manifested by reproducible methylation differences, may be used to detect PaC patients.
In conclusion, we demonstrate that epigenetic events play a role in PPARG expression.
A recent review by Baylin and Ohm [ 18] have demonstrated that epigenetic events may lead to LOH and mutations of many genes which may further underline the importance of epigenetic mechanisms in cancer initiation and progression.
Recent studies have demonstrated that hyperglycaemia may induce epigenetic changes and thereby increase expression of pro-inflammatory genes in vascular cells, which subsequently may increase the risk for diabetic complications [ 17– 20].
In addition to these well-defined genetic alterations, we and others have demonstrated that epigenetic TSG inactivation may be a feature of neuroblastoma.
Therefore, a typical SCNT embryo may be transcriptionally close to (euchromatin), but epigenetically far from (heterochromatin), normal embryos, demonstrating that epigenetic but not expression barriers limit reprogramming efficiency [ 15].
